Loading mutual fund details…
Tata India Pharma & Healthcare Fund-Direct Plan-Growth is an equity scheme managed by Tata Mutual Fund. Over rolling three-year windows since inception, investors earned a median compounded return of 21.68%, with the bottom and top quartiles at 18.11% and 23.87% respectively. It has ranked in the top half of its category for 2 of the last 2 reported years. The total expense ratio is 0.83% on assets of ₹1,325Cr. The fund is currently managed by Rajat Srivastava, appointed within the last year.
Lower is better.
This scheme classifies as Large-Blend on the 3x3 equity style box, with 85% of its portfolio classified as of 2026-05-29.
| Holding | Sector |
|---|
| Window | Min | P25 | Median |
|---|
Point-in-time CAGRs cherry-pick a single start date. The chart below shows the distribution of every possible rolling start over the fund's history, so you see the range of investor outcomes — not just one date's number.
Backtested SIP outcomes across both rolling-window scenarios and named historical stress events (COVID, Election uncertainty, Russia/Ukraine, etc.), plus per-manager alpha during their tenure on this scheme.
Same fund, monthly SIPs over rolling 1/3/5-year windows.
Mutual fund investments are subject to market risks. Read all scheme-related documents carefully. Past performance is not indicative of future results. MintByte is an AMFI-registered Mutual Fund Distributor (ARN-314872) and APMI member (APRN-01658). MintByte does not issue buy/sell recommendations on specific securities — the site is an educational data and analytics platform. Star ratings on this page reflect a 3-year category-quartile position computed in-house and are educational only.
Mutual fund schemes are subject to market risk. Read all scheme-related documents carefully before investing. Past performance is not indicative of future results. MintByte is an AMFI-registered mutual fund distributor (ARN-314872). MintByte does not issue buy/sell recommendations on specific securities — the site is an educational data and analytics platform. Not investment advice. Methodology · How we earn.
In-house derivations using 3-year daily NAV vs benchmark. See methodology.
| Weight |
|---|
| SUN PHARMACEUTICAL INDUSTRIES LTD. | Healthcare | 9.87% |
| HEALTHCARE GLOBAL ENTERPRISES LTD | Healthcare | 5.45% |
| ABBOTT INDIA LIMITED | Healthcare | 5.37% |
| MAX HEALTHCARE INSTITUTE LIMITED | Healthcare | 5.17% |
| CIPLA LIMITED | Healthcare | 5.07% |
| APOLLO HOSPITALS ENTERPRISE LIMITED | Healthcare | 4.06% |
| MANKIND PHARMA LIMITED | Healthcare | 3.73% |
| FORTIS HEALTHCARE LIMITED. | Healthcare | 3.55% |
| BAYER CROPSCIENCE LIMITED | Basic Materials | 3.34% |
| METROPOLIS HEALTHCARE LIMITED | Healthcare | 3.07% |
| LUPIN LIMITED | Healthcare | 2.94% |
| SYNGENE INTERNATIONAL LIMITED | Healthcare | 2.94% |
| Sai Life Sciences Limited | Healthcare | 2.63% |
| ALKEM LABORATORIES LIMITED | Healthcare | 2.49% |
| GLAXOSMITHKLINE PHARMACEUTICALS LTD | Healthcare | 2.44% |
| NEULAND LABORATORIES LIMITED | Healthcare | 2.41% |
| JB Chemicals & Pharmaceuticals Limited | Healthcare | 2.21% |
| GLOBAL HEALTH LIMITED | Healthcare | 2.16% |
| FDC LIMITED | Healthcare | 1.94% |
| AJANTA PHARMA LIMITED | Healthcare | 1.90% |
| VIJAYA DIAGNOSTIC CENTRE LIMITED | Healthcare | 1.72% |
| SANOFI INDIA LIMITED | Healthcare | 1.68% |
| PROCTER & GAMBLE HEALTH LIMITED | Healthcare | 1.55% |
| TORRENT PHARMACEUTICALS LIMITED | Healthcare | 1.01% |
| CORONA REMEDIES PRIVATE LIMITED | Healthcare | 0.77% |
| Sector | Holdings | Weight |
|---|---|---|
| Healthcare | 26 | 93.74% |
| Chemicals | — | 5.19% |
| Financial Services | 1 | 0.67% |
Active bets vs the average Equity fund. Biggest deviations shown first.
Accent bar = fund's actual sector weight. Vertical black tick = category average for the same sector. Green overlay = overweight, dashed red = underweight. The biggest active bets show first.
| P75 |
|---|
| Max |
|---|
| Positive % |
|---|
| 1Y | -10.77% | 1.07% | 16.33% | 39.09% | 63.19% | 77.9% |
| 3Y | 14.15% | 18.11% | 21.68% | 23.87% | 27.96% | 100.0% |
| 5Y | 14.69% | 15.93% | 18.21% | 20.71% | 24.28% | 100.0% |
Each cell is one year. Q1 = top quartile within the AMFI category for that period. Cell label is the last two digits of the year.
Top-10 weight 48.7% means concentration is in line with most actively-managed Indian equity funds. Effective-N is the inverse Herfindahl index — a measure of "how many positions effectively drive the fund" after weighting. Category: Equity.
Compounding maths on a notional ₹10 lakh lumpsum at 12% gross annual return. Green bar is what you'd have without the fee; red overlay is the fee drag. Fee is constant in this scenario — actual outcomes depend on real returns and any future TER changes.
What an investor SIPping into this fund actually got during named market shocks.
Each row is a back-tested SIP — monthly contribution over the regime's duration, no fees adjustment beyond NAV-baked TER. XIRR is the annualised IRR of those cashflows; Abs return is the absolute cash-on-cash; Max DD is the deepest drawdown experienced mid-investment. Past performance is not indicative of future results.
Alpha is the annualised excess return vs benchmark over the manager's tenure on this scheme. Beat-benchmark = total return beat the index over the same window.